| abstract |
The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having the formula I: n wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6-10 aryl, and n wherein each Rc is independently selected from the group comprising H, C 1-6 alkyl, C 2-6 alkynyl, C 2-6 alkynyl and an hydroxy protecting group; and n wherein said compound is substantially in the form of the (−) enantiomer. |